Antibody Screening News and Research

RSS

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer.

8 Aug 2016

Tanaka develops world's first kit to directly detect ZIKA virus in blood

Tanaka Holdings Co., Ltd. announced today that Tanaka Kikinzoku Kogyo K.K., which operates the Tanaka Precious Metals manufacturing business, has developed the world's first kit able to directly detect the ZIKA virus in blood. The kit is capable of rapid ZIKV detection in just 10 to 15 minutes.

7 Jun 2016

Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

In its commitment to provide diagnostic insights that enhance patient care and outcomes, Quest Diagnostics will automatically perform molecular testing on all patient specimens whose antibody screening results indicate hepatitis C virus infection, and remove standalone positive antibody screening as a test option.

From Quest Diagnostics 8 Dec 2015

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

17 Nov 2015

NYUCD receives NIH grant to develop POC test to detect HIV antibodies and viral RNA

New York University College of Dentistry has received a sub-award in the amount of $335,000 from a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health to complete the development of a fully automated self-confirming assay that can simultaneously detect HIV/AIDS antibodies and viral RNA from the AIDS virus in a single specimen.

29 Mar 2015

Vanderbilt examines ability of drug abatacept to prevent type 1 diabetes

Vanderbilt's Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

17 Sep 2013

UC Davis Health System develops new screening strategy for lethal stage of TB in Asia

More than 20,000 people in Pakistan are being tested for the potentially deadly stage of tuberculosis using a new strategy developed at UC Davis Health System to effectively detect the disease in children for the first time.

22 Aug 2013

Researchers create new ultra-sensitive tool for chemical, DNA and protein analysis

Utilizing optical characteristics first demonstrated by the ancient Romans, researchers at the University of Illinois at Urbana-Champaign have created a novel, ultra-sensitive tool for chemical, DNA, and protein analysis.

16 Feb 2013

Trellis, OMT enter collaboration to generate human antibodies

Trellis Bioscience LLC and Open Monoclonal Technology, Inc. today announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT's OmniRat platform.

8 Oct 2012

CDC recommends hepatitis C screening for all patients born from 1945-1965

Without other risk factors, all Americans born between 1945 and 1965 should have a one-time screening for the hepatitis C virus (HCV) according to new recommendations being published early online today in Annals of Internal Medicine, the flagship journal of the American College of Physicians. The Centers for Disease Control and Prevention (CDC) also recommends that all persons identified with HCV should receive a brief alcohol screening and intervention and be referred to appropriate care and treatment services for HCV and related conditions.

17 Aug 2012

Integral Molecular receives U.S. patent for methodology that generates Lipoparticles

Integral Molecular, a leader in membrane protein reagents and services, announces the issuance of a key patent protecting its methodology for generating Lipoparticles, which provide highly-concentrated membrane proteins in their native conformation for antibody and drug discovery applications focused on membrane protein targets such as G protein-coupled receptors (GPCRs), ion channels, and transporters.

4 May 2012

Quotient's ALBAcyte Reagent Red Blood Cell products receive U.S. FDA license

Quotient Biodiagnostics, Inc., a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAcyte Reagent Red Blood Cell products have been licensed for sale in the USA by the Food and Drug Administration.

19 Jan 2012

Study: Birth cohort screening for HCV is cost effective in primary care setting

According to a new study being published early online in Annals of Internal Medicine, the flagship journal of the American College of Physicians, birth cohort screening for hepatitis C is cost effective in the primary care setting.

5 Nov 2011

CRANN partnership with Merck Millipore on research

CRANN, the Science Foundation Ireland funded nanoscience research institute, based at Trinity College Dublin, has today announced a new commercial partnership worth over €130,000 with Merck Millipore, a biotech and pharmaceutical company based in Cork. As part of the research programmes, CRANN will assist Merck Millipore to further develop the nanostructures of their products’ artificial membranes, that are widely used for medical and diagnostic devices, and to deliver new products with improved membrane performances. Artificial membranes are used in a wide array of products such as lab filtration devices, antibody screening kits and blood typing products.

21 Sep 2011

Symptom-based viral load testing detects HIV in MSM

Testing for HIV when flu-like symptoms develop may offer a cost-effective alternative for early detection of HIV infection in men who have sex with men (MSM), reports a study in the journal AIDS.

31 Aug 2011

Luminex 2010 revenue increases 17% to $141.6 million

Luminex Corporation today announced financial results for the fourth quarter and year ended December 31, 2010. Recent

From Luminex 8 Feb 2011

One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

One Lambda Inc., a leading manufacturer and supplier of quality products and technology for the HLA transplant community, and Luminex Corporation have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA).

From Luminex 8 Dec 2010

OPKO acquires major share in Fabrus

OPKO Health, Inc. announced that it has made an investment in Fabrus, LLC, a privately held early stage biotechnology company with next generation therapeutic antibody drug discovery and development capabilities. In exchange for the Company's investment, the Company acquired approximately 13% of Fabrus' outstanding membership interests on a fully diluted basis.

4 Nov 2010

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Genmab A/S announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.

13 Oct 2010

Integral Molecular receives patent for Lipoparticle membrane protein technology

Integral Molecular, Inc. today announced the issuance of a key patent covering its technology for deriving high concentrations of membrane proteins. The patent, issued by the U.S. Patent and Trademark Office, covers the core composition of Integral Molecular's Lipoparticle technology, a novel cell-free format for deriving highly-concentrated membrane proteins for antibody development, drug discovery, and biomedical research.

28 Jul 2010